Immunic Stock Analysis

IMUX -  USA Stock  

USD 8.52  0.05  0.59%

Immunic price slide over the last few months may raise some interest from investors. The stock closed today at a share price of 8.52 on 121,111 in trading volume. The company executives were not very successful in positioning the firm resources to exploit market volatility in September. However, diversifying your holdings with Immunic or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.08. This high volatility is attributed to the latest market swings and not so good earnings reports for some of the Immunic partners.
Please see Risk vs Return Analysis.

Immunic Stock Analysis 

The Immunic stock analysis report makes it easy to digest most publicly released information about Immunic and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Immunic Stock analysis module also helps to analyze the Immunic price relationship with some important fundamental indicators such as market cap and management efficiency.

Immunic Stock Analysis Notes

About 25.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.12. Some equities with similar Price to Book (P/B) outperform the market in the long run. Immunic recorded a loss per share of 2.81. The entity had not issued any dividends in recent years. The firm had a split on the 15th of April 2019. Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. t and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 45 people. To learn more about Immunic call Daniel Vitt at 332 255 9818 or check out

Immunic Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Immunic's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Immunic or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Immunic generated a negative expected return over the last 90 days
Immunic has high historical volatility and very poor performance
Immunic was previously known as Vital Therapies and was traded on NMS Exchange under the symbol VTL.
Net Loss for the year was (76.54 M) with loss before overhead, payroll, taxes, and interest of (4.91 K).
Immunic currently holds about 87.17 M in cash with (67.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.32.
Immunic has a very weak financial position based on the latest SEC disclosures
Roughly 25.0% of the company shares are held by company insiders
Latest headline from Immunic gains 3.34 percent on Moderate Volume October 15 -

Immunic Upcoming and Recent Events

Earnings reports are used by Immunic to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Immunic previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report4th of November 2021
Next Earnings Report25th of February 2022
Next Fiscal Quarter End30th of September 2021
Next Fiscal Year End25th of February 2022
Last Quarter Report30th of June 2021
Last Earning Announcement30th of September 2020

Immunic Largest EPS Surprises

Earnings surprises can significantly impact Immunic's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Immunic SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Immunic prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Immunic investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Immunic specific information freely available to individual and institutional investors to make a timely investment decision.
6th of August 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
19th of July 2021
Financial Statements and Exhibits. Entry into a Material Definitive Agreement
12th of July 2021
Financial Statements and Exhibits. Other Events
1st of July 2021
Financial Statements and Exhibits. Other Events
14th of June 2021
Financial Statements and Exhibits. Other Events. Submission of Matters to a Vote of Security Holders. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
6th of May 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
19th of April 2021
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Entry into a Material Definitive Agreement
31st of March 2021
Financial Statements and Exhibits. Unregistered Sales of Equity Securities. Entry into a Material Definitive Agreement

Immunic Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Immunic is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Immunic backward and forwards among themselves. Immunic's institutional investor refers to the entity that pools money to purchase Immunic's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Golden Green IncCommon Shares87.1 K771 K
Omega Fund Management LlcCommon Shares1.8 M21.9 M
Fmr LlcCommon Shares1.2 M14.6 M
Blackrock IncCommon Shares1.1 M13.8 M
Rtw Investments LpCommon Shares920.8 K11.3 M
Vanguard Group IncCommon Shares711.8 K8.7 M
Artal Group SaCommon Shares700 K8.6 M
Note, although Immunic's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Immunic Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 182.91 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Immunic's market, we take the total number of its shares issued and multiply it by Immunic's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Immunic Profitablity

Immunic's profitability indicators refer to fundamental financial ratios that showcase Immunic's ability to generate income relative to its revenue or operating costs. If, let's say, Immunic is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Immunic's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Immunic's profitability requires more research than a typical breakdown of Immunic's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2021
Return on Average Assets(0.36) (0.39) 
Return on Average Equity(0.39) (0.42) 
Return on Invested Capital 50.15  42.88 

Management Efficiency

The entity has return on total asset (ROA) of (34.74) % which means that it has lost $34.74 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (76.76) %, meaning that it created substantial loss on money invested by shareholders. Immunic management efficiency ratios could be used to measure how well immunic manages its routine affairs as well as how well it operates its assets and liabilities. Return on Average Assets is likely to drop to -0.39 in 2021. Return on Average Equity is likely to drop to -0.42 in 2021. Immunic Total Assets are fairly stable at the moment as compared to the past year. Immunic reported Total Assets of 167.86 Million in 2020. Assets Non Current is likely to rise to about 36.8 M in 2021, whereas Current Assets are likely to drop slightly above 105.9 M in 2021.
Last ReportedProjected for 2021
Book Value per Share 10.14  10.94 
Enterprise Value over EBIT(4.00) (4.32) 
Enterprise Value over EBITDA(4.19) (4.52) 
Price to Book Value 2.00  2.32 
Tangible Assets Book Value per Share 8.61  8.84 
Enterprise Value184.3 M175.3 M
Tangible Asset Value134.9 M107.6 M

Technical Drivers

As of the 19th of October, Immunic retains the risk adjusted performance of (0.012678), and Market Risk Adjusted Performance of (0.1). Immunic technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We are able to break down and analyze data for nineteen technical drivers for Immunic, which can be compared to its competitors. Please check out Immunic coefficient of variation, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to decide if Immunic is priced fairly, providing market reflects its last-minute price of 8.52 per share. Given that Immunic has jensen alpha of (0.14), we strongly advise you to confirm Immunic's regular market performance to make sure the company can sustain itself at a future point.

Immunic Price Movement Analysis

The output start index for this execution was six with a total number of output elements of fifty-five. The Exponential Moving Average is calculated by weighting recent values of Immunic more heavily than older values. View also all equity analysis or get more info about exponential moving average overlap studies indicator.

Immunic Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Immunic insiders, such as employees or executives, is commonly permitted as long as it does not rely on Immunic's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Immunic insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Immunic Predictive Daily Indicators

Immunic intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Immunic stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Immunic Forecast Models

Immunic time-series forecasting models is one of many Immunic's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Immunic's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Immunic Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Immunic stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Immunic shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Immunic. By using and applying Immunic Stock analysis, traders can create a robust methodology for identifying Immunic entry and exit points for their positions.
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. t and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 45 people.

Current Immunic Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Immunic analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Immunic analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
52.56Strong Buy9Odds
Immunic current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Immunic analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Immunic stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Immunic, talking to its executives and customers, or listening to Immunic conference calls.
Immunic Analyst Advice Details

Immunic Stock Analysis Indicators

Immunic stock analysis indicators help investors evaluate how Immunic stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Immunic shares will generate the highest return on investment. By understating and applying Immunic stock analysis, traders can identify Immunic position entry and exit signals to maximize returns.
Quick Ratio6.46
Fifty Two Week Low6.96
Shares Short Prior Month1.64M
Average Daily Volume Last 10 Day234.93k
Average Daily Volume In Three Month267.42k
Shares Percent Shares Out3.67%
Short Percent Of Float4.11%
Forward Price Earnings-2.31
Float Shares18.97M
Fifty Two Week High28.21
Enterprise Value To Ebitda-2.60
Fifty Day Average9.15
Two Hundred Day Average11.66
Please see Risk vs Return Analysis. Note that the Immunic information on this page should be used as a complementary analysis to other Immunic's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Complementary Tools for Immunic Stock analysis

When running Immunic price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
The market value of Immunic is measured differently than its book value, which is the value of Immunic that is recorded on the company's balance sheet. Investors also form their own opinion of Immunic's value that differs from its market value or its book value, called intrinsic value, which is Immunic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunic's market value can be influenced by many factors that don't directly affect Immunic underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunic's value and its price as these two are different measures arrived at by different means. Investors typically determine Immunic value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.